Retatrutide + NAD+Beginner Protocol for Improved Fat Loss and Preventing Energy Crashes

Retatrutide is a GLP-1/GIP/Glucagon triple agonist that creates a powerful caloric deficit—but that deficit depends on NAD+ to work. Without adequate NAD+, mobilized fat doesn't oxidize efficiently, energy crashes, and progress stalls. This protocol pairs the two from day one: retatrutide for the deficit, NAD+ to keep beta-oxidation and energy production running through it.

Who This Is For

First-time peptide users who want:

• Clear structure with minimal complexity
• Predictable weight loss without energy collapse
• A foundation for more advanced protocols later

The goal is not aggressive weight loss at the expense of overall health. It is metabolic recalibration—restoring the body's ability to burn stored fuel without the fatigue, cravings, and rebounds that accompany GLP-1 monotherapy.

Why These Two Together

Retatrutide (LY3437943, developed by Eli Lilly) is a triple agonist that creates the conditions for body weight reduction through simultaneous activation of three hormone receptor pathways:

Retatrutide's moderate GLP-1 (0.5×) provides appetite control without the intense nausea of full GLP-1 agonists like semaglutide. The strong GIP signal (2×) drives insulin efficiency and fat metabolism. The attenuated glucagon (0.2×) maintains hepatic fat oxidation without hyperglycemic effects.

The result is a deficit that feels natural rather than forced. Unlike single-target incretin mimetics, retatrutide's multi-pathway approach keeps hunger quiet while metabolic rate holds.

But mobilized fat still needs to be burned. That's where NAD+ becomes essential.

In a deficit, cells lean heavily on β-oxidation—the pathway that converts fat to ATP. This pathway is NAD+-hungry. When NAD+ runs short, fat is mobilized but not efficiently converted to energy. Fatigue sets in. Cravings return. Progress stalls.

Maintaining NAD+ keeps the fat-burn → ATP chain moving. Energy stays stable while the deficit does its work.

Preventing the Metabolic Wall

Users of GLP-1 drugs often hit a "wall" around months 3-6. Weight loss stalls. Energy crashes. The medication seems to stop working.

This isn't drug failure. It's metabolic exhaustion—and it's predictable.

What's Happening

Retatrutide mobilizes stored fat aggressively through its triple-receptor mechanism. That fat needs to be converted to ATP through beta-oxidation—the pathway that breaks fat into usable energy. Every step of beta-oxidation requires NAD+.

The depletion spiral:

1. Caloric deficit increases energy demand
2. Beta-oxidation runs at high capacity
3. NAD+ consumption outpaces production
4. Mitochondrial efficiency drops
5. Fatigue sets in, progress stalls

The Competing Demands Problem

Your NAD+ pool serves four masters simultaneously—and they all compete for the same finite resource:

When energy production dominates the pool—as it does during aggressive metabolic protocols—the other systems get rationed. Recovery slows. Stress adaptation weakens. The "wall" materializes.

The Solution: Maintain the NAD+ Floor

Supplementing 100-200mg NAD+ five days weekly keeps all four systems adequately fueled:

• Energy production runs without exhausting other pathways
• DNA repair continues in the background
• Sirtuin-driven adaptation stays active
• The depletion spiral never gains momentum

This is the logic behind the combination: retatrutide opens the fuel lines; NAD+ keeps the engine running efficiently.

For deeper understanding of NAD+ mechanisms, including the CD38/senescent cell loop that drives age-related depletion, see the complete NAD+ guide.

Clinical Trial Results

Retatrutide has demonstrated exceptional weight loss outcomes in clinical trials. The landmark NEJM 2023 study (Jastreboff et al.) reported:

These results exceed outcomes seen with single-receptor GLP-1 agonists like semaglutide (~15% at comparable timepoints). The triple-receptor mechanism—engaging GLP-1, GIP, and glucagon pathways simultaneously—appears to provide enhanced fat oxidation and metabolic rate preservation compared to GLP-1 monotherapy.

For this beginner protocol, we use conservative doses (0.5–4 mg weekly) to prioritize tolerability while still achieving meaningful results. Expect 10–20 lbs of weight loss over 12 weeks depending on starting weight, dose titration, and lifestyle adherence.

Current Status & Availability

As of February 2026, retatrutide (development code: LY3437943) is not FDA approved. It remains in Phase 3 clinical trials conducted by Eli Lilly. The compound is being studied under the brand name development program for obesity and type 2 diabetes indications.

Key regulatory milestones:

• Phase 2 results published in NEJM (2023)
• Phase 3 trials ongoing (NCT05929066, NCT06070792)
• FDA approval anticipated: late 2026–2027 (pending trial outcomes)

Current access is limited to clinical trial participation and research settings. This protocol guide is for educational purposes—discuss any peptide use with a qualified healthcare provider.

Dosing

Use our peptide dosing calculator to determine your exact injection volume based on reconstitution concentration. For preparation instructions, see the reconstitution guide.

Weekly Schedule (Example)

Adjust to your chosen retatrutide frequency. Consistency matters more than the specific schedule.

Timeline: What to Expect

Lifestyle Foundation

This protocol works on top of, not instead of, basic metabolic hygiene.

When Progress Stalls

Dose escalation should be gradual and methodical. If weight loss plateaus:

1. Re-check protein, steps, and hydration. Ensure you're not under-eating to the point of rebound cravings.
2. If nausea is minimal and you've held 4+ weeks at current level, titrate retatrutide by +0.5 mg/week.
3. Move NAD+ to 200 mg per dose or add one additional NAD+ day.
4. Maintain new dose for 4+ weeks before any further titration.

Managing Side Effects

Monitoring

What Comes Next

After 12 weeks, two paths:

Maintenance: Reduce retatrutide to 1–2 mg/week. NAD+ at 100 mg on training or high-stress days. Continue lifestyle foundation.

Progress to Intermediate: Add L-Carnitine and MOTS-c to increase fat oxidation capacity and preserve lean mass during deeper recomposition. See Retatrutide Recomp Protocol.

Contraindications

• Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
• Active pancreatitis
• Pregnancy or breastfeeding
• Severe GI motility disorders

Discuss with a physician if you have a history of gallbladder disease, diabetic retinopathy, or are on glucose-lowering medications that may need adjustment.

FAQ

What is the best retatrutide starting dose for beginners?

The recommended starting dose is 0.5 mg per week via subcutaneous injection. This allows your body to adapt to the triple-receptor agonist gradually, minimizing side effects like nausea. Most users wait at least 4 weeks before considering a dose increase to 1 mg, then progress in 0.5 mg increments as tolerated. Rushing dose escalation often leads to unnecessary GI discomfort without faster results.

How much weight can you lose on retatrutide?

Clinical trial data (NEJM 2023) showed participants losing up to 24% of body weight at 48 weeks on higher doses (12 mg weekly). In a 12-week beginner protocol using conservative doses (0.5–4 mg), expect 10–20 lbs of weight loss depending on starting weight, dose, and lifestyle factors. Initial losses in weeks 1–4 include water and glycogen depletion; sustained fat loss averages 1–2 lbs per week in subsequent phases.

How does retatrutide compare to semaglutide (Ozempic)?

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors, compared to semaglutide which targets only GLP-1. This broader mechanism provides several advantages: enhanced fat oxidation through glucagon receptor activation, improved insulin sensitivity via GIP, and potentially better metabolic rate preservation during weight loss. Early trial data suggests 5–10% greater weight loss percentages with retatrutide versus semaglutide at comparable timepoints, though direct head-to-head comparison trials are ongoing.

How does retatrutide compare to tirzepatide (Mounjaro)?

Tirzepatide is a dual GLP-1/GIP agonist, while retatrutide adds glucagon receptor activation as a third pathway. The glucagon component is significant: it increases hepatic fat oxidation, meaning the liver actively burns more fat rather than just reducing appetite. In clinical trials, retatrutide produced greater absolute weight loss percentages than tirzepatide (24% vs ~21% at highest doses), though tirzepatide has more long-term safety data and is already FDA-approved. For beginners, both are effective—retatrutide may offer faster results, while tirzepatide has a more established track record.

Is retatrutide FDA approved?

As of February 2026, retatrutide is not FDA approved. It remains in Phase 3 clinical trials conducted by Eli Lilly under development code LY3437943. FDA approval is anticipated in late 2026–2027 pending successful trial completion. Current use outside clinical trials is limited to research settings—always discuss peptide use with a healthcare provider.

Why combine retatrutide with NAD+?

NAD+ supports the beta-oxidation pathway that converts mobilized fat into ATP (cellular energy). When retatrutide creates a caloric deficit, your body mobilizes stored fat, but that fat still needs to be burned efficiently. During significant caloric restriction, cellular NAD+ demand increases substantially. Supplementing NAD+ (100–200 mg, 5 days per week) helps maintain energy levels, reduces fatigue common with GLP-1 agonists, and may optimize the fat-burning cascade initiated by retatrutide. Think of NAD+ as keeping the metabolic engine running smoothly while retatrutide opens the fuel lines.

How long does it take for retatrutide to work?

Appetite suppression typically begins within 48–72 hours of the first injection as the GLP-1 and GIP receptor pathways activate. Measurable weight loss (2–4 lbs, including water/glycogen) is common in the first 4 weeks. Steady fat loss of 1–2 lbs per week typically begins in weeks 5–8 as metabolic adaptation occurs. Full protocol duration is 12 weeks for optimal results, after which you can transition to maintenance dosing or progress to an intermediate protocol.

Related Topics

• GLP-1 Compounds Tool — interactive comparison with trial data on weight loss and body composition
• Retatrutide Guide — complete retatrutide overview
• NAD+ Guide — why NAD+ matters for metabolic function
• Retatrutide Recomp Protocol — advanced dual-axis protocol

References

• Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM 2023. https://doi.org/10.1056/NEJMoa2301972
• Yoshino J, et al. NAD+ Intermediates: The Biology and Therapeutic Potential. Cell Metabolism 2021. https://doi.org/10.1016/j.cmet.2020.11.007
• Covarrubias AJ, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology 2020.
• Covarrubias AJ, et al. Senescent cells promote tissue NAD+ decline during ageing. Nature Metabolism 2020. https://www.nature.com/articles/s42255-020-00305-3
• Camacho-Pereira J, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction. Cell Metabolism 2016.

Educational content only. Some compounds discussed are FDA-approved medications; others are research peptides without FDA approval — not due to safety concerns, but because unpatentable compounds cannot justify the required trial investment. Work with a qualified healthcare provider before using any protocol.